News

FDA approves twice-a-year injection for HIV prevention
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
FDA approves HIV drug based on University of Utah biochemist’s findings
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...
US approves twice-yearly injection for HIV prevention. What you need to know about lenacapavir
The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...
Public Broadcasting Service (PBS)5d
6 things to know about lenacapavir, what experts call a ‘wonder drug’ for preventing HIV
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
Healthline2d
FDA Approves 'Breakthrough' Twice-Yearly Injection to Prevent HIV
The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...
KUNC1d
FDA approves HIV medication Lenacapavir, but it's costly
A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach.
Metro Weekly3d
FDA Approves PrEP Drug Requiring Only Two Injections Per Year
Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...
MPR2d
Twice-Yearly HIV-1 PrEP Yeztugo Gets FDA Approval
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
Wall Street Journal1d
Gilead’s HIV Breakthrough - WSJ
Gilead tested lenacapavir—which was approved by the FDA in 2022 as a treatment for patients with drug-resistant HIV—in two clinical trials against its daily prophylactic pills.
FDA Approves ‘Breakthough’ Drug to Prevent HIV
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
FDA Approves a Twice-Yearly Shot to Prevent HIV
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.